Anne-Laure Papa

Anne-Laure Papa

Auto-generated profile, based on publicly available information

Anne-Laure Papa

Department of Biomedical Engineering, School of Engineering and Applied Science, The George Washington University, Washington, DC, 20052, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
APAnne-Laure Papa
Anne-Laure Papa
AJAmanda Jiang
Amanda Jiang
NKNetanel Korin
Netanel Korin
MCMichelle B. Chen
Michelle B. Chen
ELErin T. Langan
Erin T. Langan
DIDonald E Ingber
Donald E Ingber
Human platelet decoys prevented thrombosis in rabbits and inhibited cancer cell aggregation and extravasation in vitro and in a mouse model.

1 August 2022 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Open access
KMKenise Morris
Kenise Morris
BSBrian Schnoor
Brian Schnoor
APAnne-Laure Papa
Anne-Laure Papa
The interaction between circulating tumor cells and platelets is a key factor in cancer metastasis. These interactions, driven by a variety of receptors, support circulating tumor cells by protecting them from immune detection, cushioning them from shear stress, and promoting their arrest at the endothelium. Additionally, platelets have been shown to accumulate in the primary tumors, promoting tumor growth and angiogenesis by releasing growth factors. Furthermore, tumor cells can interact with platelets by inducing aggregation, which further protects cancer cells. However, the platelet cancer cell interplay also offers new approaches to develop targeted therapies. The accumulation of platelets in tumors has successfully been leveraged to deliver chemotherapeutics and imaging agents. Likewise, these platelet-based interactions have been utilized to target cancer cells in circulation. Although these current systems have limitations including drug loading and storage, leveraging platelet-cancer cell interactions to effectively target circulating tumor cells and tumors shows great promise for future cancer treatments.

14 September 2021 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
PDF file
CBColette Bilynsky
Colette Bilynsky
Nadine MillotNadine Millot
Nadine Millot
APAnne‐Laure Papa
Anne‐Laure Papa
Improving the efficacy and spatial targeting of radiation therapy while sparing surrounding normal tissues has been a guiding principle for its use in cancer therapy. Nanotechnologies have shown considerable growth in terms of innovation and the development of new therapeutic approaches, particularly as radiosensitizers. The aim of this study was to systematically review how nanoparticles (NPs) are used to enhance the radiotherapeutic effect, including preclinical and clinical studies. Clinicaltrials.gov was used to perform the search using the following terms: radiation, cancer, and NPs. In this review, we describe the various designs of nano‐radioenhancers, the rationale for using such technology, as well as their chemical and biological effects. Human trials are then discussed with an emphasis on their design and detailed clinical outcomes.

29 July 2024 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
BSBrian Schnoor
Brian Schnoor
KMKenise Morris
Kenise Morris
RKRegina K. Kottana
Regina K. Kottana
RMRebekah Muldoon
Rebekah Muldoon
JBJaeden Barron
Jaeden Barron
APAnne‐Laure Papa
Anne‐Laure Papa

7 December 2020 in Small
Verified
Journal Article
Open access
PDF file
RKRegina Komal Kottana
Regina Komal Kottana
Lionel MauriziLionel Maurizi
Lionel Maurizi
BSBrian Schnoor
Brian Schnoor
KMKenise Morris
Kenise Morris
JWJessica Ann Webb
Jessica Ann Webb
APAnne‐Laure Papa
Anne‐Laure Papa
Iron oxide nanoparticles are developed for various biomedical applications, however, there is limited understanding regarding their effects and toxicity on blood components. The particles traveling in circulation inevitably interact with blood cells and plasma proteins and may interfere with hemostasis. Specifically, this study focuses on the influence of superparamagnetic iron oxide nanoparticles (SPIONs) coated with a biocompatible polymer, polyvinyl alcohol (PVA), on platelet function. Here, engineered SPIONs that are functionalized with various PVA coatings to provide these particles with different surface charges and polymer packing are described. These formulations are assessed for any interference with human platelet functions and coagulation, ex vivo. Positively charged SPIONs induce a significant change in platelet GPIIb‐IIIa conformation, indicative of platelet activation at the dose of 500 µg mL−1. Remarkably, engineered PVA(polyvinyl alcohol)‐SPIONs all display a robust dose‐dependent anti‐platelet effect on platelet aggregation, regardless of the PVA charge and molecular weight. After assessing hypotheses involving SPION‐induced steric hindrance in platelet–platelet bridging, as well as protein corona involvement in the antiplatelet effect, the study concludes that the presence of PVA‐SPIONs induces fibrinogen conformational change, which correlates with the observed dose‐dependent anti‐platelet effect.

19 August 2022 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
BSBrian Schnoor
Brian Schnoor
APAnne-Laure Papa
Anne-Laure Papa
Lyophilized platelets have been explored as a potential hemostatic agent due to their long-term ambient storage capabilities that make them readily available in various scenarios. Additionally, their high biocompatibility and the key role of platelet interactions in various clinical conditions make them a promising platform for drug delivery. To explore these applications and for wider clinical deployment, the interactions between lyophilized platelets and fresh platelets must be examined. This project characterized receptor expression on the lyophilized platelet surface and their ability to bind fibrinogen using flow cytometry. The effect of lyophilized platelets on aggregation of unaltered platelets was assessed using light transmission aggregometry while the effect on adhesion was evaluated using static and microfluidic assays. Lyophilized platelets maintained significant levels of GPIIb and GPVI receptors on their surface, though the expression was reduced from fresh platelets. Additionally, lyophilized platelets maintained GPIb expression similar to fresh platelets. Furthermore, 15.8% of the lyophilized platelets exhibited the active conformation of the GPIIb/IIIa receptor, indicating a significant increase over fresh platelets. Lyophilized platelets also exhibited an increase in exposed phosphatidylserine and fibrinogen binding. Despite the effect of lyophilized platelets in promoting the adhesion of fresh platelets on a collagen-coated surface, their net effect was inhibitory on platelet aggregation. This study demonstrates that lyophilized platelets can have paradoxical effects on platelet adhesion and aggregation, which could have an impact for clinical applications. Detailed characterization and engineering of these effects will be important for their continued development as a drug delivery platform.